Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health condition at a...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low expression of the CCL5 gene and low serum concentrations of CCL5 in severe invasive group a streptococcal disease.

Infection·2024
Same author

A novel SERPINA12 variant and first European patients with diffuse palmoplantar keratoderma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Obstetric and perinatal risks after the use of donor sperm: A systematic review and meta-analysis.

European journal of obstetrics, gynecology, and reproductive biology·2022
Same author

A novel desmoplakin mutation causes dilated cardiomyopathy with palmoplantar keratoderma as an early clinical sign.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Founder effects facilitate the use of a genotyping-based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia.

Journal of internal medicine·2021
Same author

Hereditary palmoplantar keratoderma - phenotypes and mutations in 64 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same journal

RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune Thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Joint effect of muscle strength and physical inactivity on risk of incident venous thromboembolism: The Tromsø Study.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Factor V Leiden as a risk factor for preterm birth--a population-based nested case-control study.

L M Hiltunen1, H Laivuori, A Rautanen

  • 1Department of Hemostasis, Finnish Red Cross Blood Service, Helsinki, Finland. leena.hiltunen@bts.redcross.fi

Journal of Thrombosis and Haemostasis : JTH
|October 16, 2010
PubMed
Summary
This summary is machine-generated.

Factor V Leiden, a genetic thrombophilia, increases the risk of late preterm birth. Other thrombophilias like FII G20210A were not associated with preterm birth risk.

Related Experiment Videos

Last Updated: Jun 8, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

  • Reproductive Medicine
  • Genetics
  • Obstetrics

Background:

  • Preterm birth is a significant cause of neonatal complications, affecting 5-13% of deliveries.
  • The role of genetic thrombophilia as a risk factor for preterm birth remains unclear.

Purpose of the Study:

  • To investigate the association between genetic thrombophilia (Factor V Leiden, FII G20210A) and preterm birth.
  • To assess other inherited and acquired variables as potential risk factors for preterm delivery.

Main Methods:

  • A population-based nested case-control study involving 100,000 pregnancies in Finland.
  • Cases (324 preterm births) and controls (752) were identified using national registers and clinical data.

Main Results:

  • Factor V Leiden (FV Leiden) showed a 2.4-fold increased risk of preterm birth, particularly late preterm birth (after 32 weeks).
  • FII G20210A was not associated with preterm birth. Twin pregnancies and a history of venous thrombosis increased risk.
  • High educational level and moderate overweight (BMI 25-29.9) exhibited protective effects.

Conclusions:

  • Maternal Factor V Leiden carriage is linked to an elevated risk of late preterm birth.
  • No association was found between FII G20210A and preterm birth.